<DOC>
	<DOCNO>NCT00544934</DOCNO>
	<brief_summary>A dose-ranging study evaluate safety , metabolism therapeutic dosing three multiple dose level GLY-230 healthy diabetic subject</brief_summary>
	<brief_title>Multiple Dose Trial Anti-glycation Agent GLY-230 Healthy Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Nondiabetic diabetic men age 1855 , engative drug screen , normal EKG , clinical chemistry . hematology parameter , HbA1c 7.5 % diabetic , give write informed consent Sctive concomitant serious medical surgical disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>